Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Breast Tumor Clear all
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

NCT00600275
View directory record Official record
Conditions
Solid Tumors, Breast Cancer, Cowden Syndrome
Interventions
BGT226
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
4
States / cities
Boston, Massachusetts • Las Vegas, Nevada • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 28, 2026, 5:36 PM EDT
Recruiting No phase listed Observational

Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer

NCT06666439
View directory record Official record
Conditions
Metastatic Invasive Lobular Carcinoma (mILC)
Interventions
circulating tumor DNA (ctDNA)
Diagnostic Test
Lead sponsor
Julia Foldi
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 28, 2026, 5:36 PM EDT
Completed Early Phase 1 Interventional

FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients

NCT01864083
View directory record Official record
Conditions
Breast Cancer
Interventions
Positron Emission Tomography (PET), Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC), Positron emission mammography (PEM) When available, MR
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 28, 2026, 5:36 PM EDT
Completed Phase 2 Interventional

Preoperative Herceptin and Navelbine for Breast Cancer

NCT00148681
View directory record Official record
Conditions
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Herceptin, Navelbine, Doxorubicin, Cyclophosphamide, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Sep 28, 2026, 5:36 PM EDT
Completed Not applicable Interventional Results available

Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients

NCT02321527
View directory record Official record
Conditions
Breast Cancer
Interventions
Perflutren Protein-Type A Microspheres Injectable Suspension, Contrast-Enhanced Ultrasound (CEUS), Biopsy + Radioactive Seed Placement, Phone Call
Drug · Device · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 28, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Everolimus Beyond Progression

NCT02269670
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
everolimus, anastrozole, letrozole, tamoxifen citrate, fulvestrant, megestrol acetate
Drug
Lead sponsor
Emory University
Other
Eligibility
19 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 28, 2026, 5:36 PM EDT
Completed Phase 2 Interventional

Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer

NCT00050141
View directory record Official record
Conditions
Breast Cancer
Interventions
ZARNESTRA, tipifarnib, R115777
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
50 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
6
States / cities
Miami, Florida • Chicago, Illinois • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 28, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional Results available

Study of Stereotactic Radiotherapy for Breast Cancer

NCT03043794
View directory record Official record
Conditions
Breast Cancer
Interventions
Stereotactic Body Radiation Therapy SBRT
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 28, 2026, 5:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Periodic Screening of Women With Denser Breast Using WBUS and DBT

NCT02643966
View directory record Official record
Conditions
Breast Cancer
Interventions
Whole breast ultrasound
Device
Lead sponsor
Wendie Berg
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
6,266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 28, 2026, 5:36 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Breast Cancer

NCT00004156
View directory record Official record
Conditions
Breast Cancer
Interventions
MUC1-KLH vaccine/QS21
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 28, 2026, 5:36 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

NCT06695845
View directory record Official record
Conditions
Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
Interventions
Zanidatamab
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
17
States / cities
Prescott, Arizona • Littleton, Colorado • Fort Myers, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 28, 2026, 5:36 PM EDT
Terminated Phase 4 Interventional

Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy

NCT00699101
View directory record Official record
Conditions
Breast Cancer
Interventions
Conture Multi-Lumen Balloon
Device
Lead sponsor
SenoRx, Inc.
Industry
Eligibility
50 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2013 · Synced Sep 28, 2026, 5:36 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery

NCT00542542
View directory record Official record
Conditions
Breast Cancer
Interventions
Paravertebral Block, Propofol, Fentanyl, Ropivacaine, Midazolam
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Sep 28, 2026, 5:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women

NCT00445445
View directory record Official record
Conditions
Breast Cancer
Interventions
physiologic testing, screening questionnaire administration, breast imaging study, radiomammography, study of high risk factors
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
40 Years and older · Female only
Enrollment
2,201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
8
States / cities
Cleveland, Ohio • Mayfield Heights, Ohio • Mentor, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 28, 2026, 5:36 PM EDT
Recruiting Phase 1Phase 2 Interventional

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366
View directory record Official record
Conditions
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer
Interventions
Rina-S, Carboplatin, Bevacizumab, Pembrolizumab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 28, 2026, 5:36 PM EDT
Recruiting Phase 2 Interventional

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

NCT06580002
View directory record Official record
Conditions
Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Genitourinary Cancer, Gynecologic Cancer, Urinary Bladder Cancer, Leukemia, Lymphoid Leukemia, Myeloma Multiple, Prostate Cancer, Pancreas Cancer, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Brain Cancer, Melanoma, Mycosis Fungoides, Kidney Cancer
Interventions
Riluzole, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 28, 2026, 5:36 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

NCT00645177
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
ABT-869, paclitaxel, Placebo for ABT-869
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
San Francisco, California • Harvey, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Sep 28, 2026, 5:36 PM EDT
Active, not recruiting Not applicable Interventional

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy

NCT06055881
View directory record Official record
Conditions
Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Cancer
Interventions
Biospecimen Collection, Surveys, Stereotactic Body Radiation Therapy (SBRT), Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 28, 2026, 5:36 PM EDT
Completed Phase 3 Interventional Results available

Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer

NCT00003830
View directory record Official record
Conditions
Breast Cancer
Interventions
conventional surgery, Sentinel node resection followed by node examination
Procedure
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
5,611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2014
U.S. locations
68
States / cities
Mobile, Alabama • Little Rock, Arkansas • Duarte, California + 61 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 28, 2026, 5:36 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

NCT00022230
View directory record Official record
Conditions
Breast Cancer
Interventions
aldesleukin, filgrastim, sargramostim, therapeutic autologous lymphocytes, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 28, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional Results available

A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant

NCT02540330
View directory record Official record
Conditions
Female Breast Carcinoma, Female Ductal Carcinoma In Situ
Interventions
Fulvestrant
Drug
Lead sponsor
Atossa Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Sep 28, 2026, 5:36 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer

NCT02547987
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, Carboplatin
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 28, 2026, 5:36 PM EDT
Completed Phase 2 Interventional

S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

NCT00015938
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, docetaxel, vinorelbine
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
99
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 28, 2026, 5:36 PM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation

NCT01856543
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Eucerin, Mometasone Furoate 0.1%
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 28, 2026, 5:36 PM EDT